From achieving global recognition in biosimilars to advancing biomanufacturing capabilities and precision therapeutics, the sector has solidified its role as a key player in the global pharmaceutical landscape. This progress underscores India’s strategic focus on leveraging its robust infrastructure, skilled talent pool, and government support to meet the evolving demands of the healthcare industry. Key developments in 2024 include an increase in biosimilar approvals, enhanced collaborations for biologics and vaccines, and a focus on potential investments in cutting-edge technologies like Artificial Intelligence (AI), continuous manufacturing, and automation through biofoundries. Looking ahead, the industry is well-positioned to align with emerging trends that are shaping the global biopharma landscape for 2025 and beyond.
These include the growing emphasis on precision medicine, a shift towards sustainable biomanufacturing practices, and an increase in demand for advanced therapies such as cell and gene therapies. With over $200 billion worth of biologic patents set to expire by 2030, Indian companies are poised to play a pivotal role in driving the next wave of innovation and accessibility in biologics and biosimilars. Let’s explore further.
Esta historia es de la edición BioSpectrum India Dec 2024 de Bio Spectrum.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición BioSpectrum India Dec 2024 de Bio Spectrum.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor? Conectar
Agilent releases nextgen HPLC systems with enhanced automation and sustainability capabilities
Agilent Technologies Inc. has announced the release of its next generation Agilent InfinityLab LC Series portfolio, which includes the 1290 Infinity III LC, 1260 Infinity III Prime LC, and 1260 Infinity III LC systems, all including the biocompatible versions.
Univercells Technologies launches miniaturised scale-X Nexo Bioreactor
Univercells Technologies has announced the launch of its latest innovation, the scale-X nexo bioreactor.
Thermo Fisher and Telangana to establish Bioprocess Design Centre for novel biotherapeutics
Thermo Fisher Scientific has announced the signing of a Memorandum of Understanding (MoU) with the Government of Telangana to establish a Bioprocess Design Centre (BDC) in Genome Valley, Hyderabad.
VFL Sciences announces launch of GreatFlo Parallel Bioreactors and Fermentors
Chennai-based VFL Sciences has announced the launch of GreatFlo Parallel, a range of seamlessly parallel Bioreactors and Fermentors at the IKMC 2024 event organised by IKP Knowledge Park at Hyderabad recently, by Dr Jitendra Kumar, Managing Director, BIRAC.
Avantor opens new innovation centre for solving life science's biggest challenges
Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, has announced the opening of its new flagship Bridgewater Innovation Centre.
Waters unveils new software to deliver lab-centric business intelligence
Waters Corporation has announced the launch of waters connect Data Intelligence software, a new cloud-based application that helps customers in regulated industries improve how they access, organise, analyse, and drive productivity from laboratory information.
INST develops unique drug delivery method to improve treatment of brain TB
Researchers at the Institute of Nano Science and Technology (INST), Mohali, have created a unique way to deliver Tuberculosis (TB) medicines directly to the brain bypassing the challenging blood-brain barrier (BBB) that limits the effectiveness of many brain TB medicines.
New way to create hydrogels from viral protein fragments for improving drug delivery
Researchers from Bose Institute, an autonomous institute of the Department of Science and Technology (DST), in Kolkata, have discovered a new way to create hydrogels using tiny protein fragments of just five amino acids from the SARS-CoV-1 virus, that could help improve targeted drug delivery & reduce side effects.
Lupin appoints Claus Jepsen as President, Global Specialty
Global pharma major Lupin has announced the appointment of Claus Jepsen as President, Global Specialty.
Shyamakant Giri to join as CEO of Gland Pharma
Gland Pharma’s Board has approved the appointment of Shyamakant Giri, as the new Chief Executive Officer (CEO) of the company.
